Results 21 to 30 of about 4,157 (190)

CYP4F2 (rs2108622) Gene Polymorphism Association with Age-Related Macular Degeneration [PDF]

open access: yesAdvances in Medicine, 2016
Background. Age-related macular degeneration is the leading cause of blindness in elderly individuals where aetiology and pathophysiology of age-related macular degeneration are not absolutely clear.Purpose. To determine the frequency of the genotype of rs2108622 in patients with early and exudative age-related macular degeneration.Methods.
Ruta Sakiene   +6 more
openaire   +2 more sources

The correlation between CYP4F2 variants and chronic obstructive pulmonary disease risk in Hainan Han population

open access: yesRespiratory Research, 2020
Background Chronic obstructive pulmonary disease (COPD) is a complex pulmonary disease. Cytochrome P450 family 4 subfamily F member 2 (CYP4F2) belongs to cytochrome P450 superfamily of enzymes responsible for metabolism, its single nucleotide ...
Yipeng Ding   +11 more
doaj   +1 more source

CYP4F2 And CYP3A5 Gene Polymorphisms And Lung Cancer In Chinese Han Population [PDF]

open access: yesClinical and Experimental Medicine, 2019
Abstract Objective: This study aimed to explore whether the polymorphisms of CYP4F2 and CYP3A5 are correlated to the risk of lung cancer development. Methods: A case-control study was conducted among 510 patients with pathologically confirmed lung cancer as the case group and 504 healthy individuals as the control group.
Ruiqing He   +8 more
openaire   +3 more sources

The influence of clinical and genetic factors on the stability of warfarin’s anticoagulant effect in patients with atrial fibrillation

open access: yesPatologìâ, 2022
The aim. To investigate the influence of clinical and genetic factors on the stability of warfarin’s anticoagulant effect in patients with atrial fibrillation (AF) during the year. Materials and methods.
Ya. M. Mykhailovskyi
doaj   +1 more source

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

open access: yesBlood, 2009
VKORC1 and CYP2C9 polymorphisms are used to predict the safe dose of oral anticoagulant therapy. A new variant of CYP4F2 (V433M) has recently been related to the required warfarin dose. We evaluated its influence in earliest response to acenocoumarol in 100 selected men who started anticoagulation (3 mg for 3 consecutive days). V433M genotype exerted a
Virginia, Pérez-Andreu   +6 more
  +7 more sources

A new pharmacogenetic algorithm to predict the most appropriate dosage of acenocoumarol for stable anticoagulation in a mixed Spanish population [PDF]

open access: yes, 2016
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.There is a strong ...
Alberto M Borobia   +11 more
core   +8 more sources

PharmGKB summary [PDF]

open access: yesPharmacogenetics and Genomics, 2015
Cytochrome p450, family 2, subfamily F, polypeptide 2 (CYP4F2) catalyzes the NADPH-dependent oxidation of the terminal carbon of long and very long-chain fatty acids, the side chains of vitamin K (K1, K2) and vitamin E (tocopherols and tocotrienols), arachidonic acid (AA), and leukotriene B4 (LTB4).
Maria L, Alvarellos   +5 more
openaire   +2 more sources

Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids [PDF]

open access: yes, 2008
Very-long-chain fatty acids (VLCFAs) have long been known to be degraded exclusively in peroxisomes via beta-oxidation. A defect in peroxisomal beta-oxidation results in elevated levels of VLCFAs and is associated with the most frequent inherited ...
Dacremont, Georges   +4 more
core   +2 more sources

Renal drug metabolism in humans: the potential for drug–endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) [PDF]

open access: yes, 2013
This item is under embargo for a period of 12 months from the date of publication, in accordance with the publisher's policy. ‘This is the peer reviewed version of the following article: Knights, K. M., Rowland, A. and Miners, J. O.
Knights, Kathleen Mary   +2 more
core   +1 more source

CYP4F2 genetic variant alters required warfarin dose

open access: yesBlood, 2008
Abstract Warfarin is an effective, commonly prescribed anticoagulant used to treat and prevent thrombotic events. Because of historically high rates of drug-associated adverse events, warfarin remains underprescribed. Further, interindividual variability in therapeutic dose mandates frequent monitoring until target anticoagulation is ...
Michael D, Caldwell   +18 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy